Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Claggett

Showing results (221-230 of 362) with videos related to

Pageof 37
Sort By:
Nature Medicine|March 30, 2026
The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trialScott D Solomon, John J V McMurray, G Michael Felker, et al.
JACC. Basic to Translational Science|December 14, 2021
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized TrialThorsten M Leucker, William O Osburn, Paula Reventun, et al.
European Heart Journal|October 30, 2013
Left ventricular dyssynchrony in patients with heart failure and preserved ejection fractionAngela B S Santos, Elisabeth Kraigher-Krainer, Natalie Bello, et al.
Journal of the American College of Cardiology|April 22, 2022
Association of Left Atrial Structure and Function With Heart Failure in Older AdultsRiccardo M Inciardi, Brian Claggett, Masatoshi Minamisawa, et al.
JAMA Cardiology|March 17, 2019
Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO StudyMasatoshi Minamisawa, Brian Claggett, David Adams, et al.
European Journal of Heart Failure|April 7, 2021
The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF)Tor Biering-Sørensen, Masatoshi Minamisawa, Jiankang Liu, et al.
The American Journal of Cardiology|January 8, 2019
Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study)Thao Huynh, Brian J Harty, Brian Claggett, et al.
The Lancet. Diabetes & Endocrinology|March 24, 2017
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trialJelena P Seferovic, Brian Claggett, Sara B Seidelmann, et al.
JACC. Heart Failure|March 26, 2024
Training the Next Generation of Data Monitoring Committee Members: An Initiative of the Heart Failure CollaboratoryThomas R Fleming, Janet Wittes, Mona Fiuzat, et al.
JACC. Heart Failure|September 8, 2014
Heart failure risk across the spectrum of ankle-brachial index: the ARIC study (Atherosclerosis Risk In Communities)Deepak K Gupta, Hicham Skali, Brian Claggett, et al.
Pageof 37

Showing results (221-230 of 362) with videos related to

Sort By:
Pageof 37
Nature Medicine|March 30, 2026
The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trialScott D Solomon, John J V McMurray, G Michael Felker, et al.
JACC. Basic to Translational Science|December 14, 2021
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized TrialThorsten M Leucker, William O Osburn, Paula Reventun, et al.
European Heart Journal|October 30, 2013
Left ventricular dyssynchrony in patients with heart failure and preserved ejection fractionAngela B S Santos, Elisabeth Kraigher-Krainer, Natalie Bello, et al.
Journal of the American College of Cardiology|April 22, 2022
Association of Left Atrial Structure and Function With Heart Failure in Older AdultsRiccardo M Inciardi, Brian Claggett, Masatoshi Minamisawa, et al.
JAMA Cardiology|March 17, 2019
Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO StudyMasatoshi Minamisawa, Brian Claggett, David Adams, et al.
European Journal of Heart Failure|April 7, 2021
The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF)Tor Biering-Sørensen, Masatoshi Minamisawa, Jiankang Liu, et al.
The American Journal of Cardiology|January 8, 2019
Comparison of Outcomes in Patients With Diabetes Mellitus Treated With Versus Without Insulin + Heart Failure With Preserved Left Ventricular Ejection Fraction (from the TOPCAT Study)Thao Huynh, Brian J Harty, Brian Claggett, et al.
The Lancet. Diabetes & Endocrinology|March 24, 2017
Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trialJelena P Seferovic, Brian Claggett, Sara B Seidelmann, et al.
JACC. Heart Failure|March 26, 2024
Training the Next Generation of Data Monitoring Committee Members: An Initiative of the Heart Failure CollaboratoryThomas R Fleming, Janet Wittes, Mona Fiuzat, et al.
JACC. Heart Failure|September 8, 2014
Heart failure risk across the spectrum of ankle-brachial index: the ARIC study (Atherosclerosis Risk In Communities)Deepak K Gupta, Hicham Skali, Brian Claggett, et al.
Pageof 37